Biopharmcatalyst LTD

launched in june 2010 by adam burden, biopharmcatalyst aims to provide wall st investors with the building blocks in forming trading ideas in biotech companies. while aimed at all investors, there is a particular emphasis placed on providing easily accessible information to the small investor on fda approval and clinical trial catalysts. the main feature of biopharmcatalyst is the fda calendar, which provides a database of upcoming clinical events, such as fda approval dates, or expected dates up clinical data releases for pharma companies. http://www.biopharmcatalyst.com/fda-calendar/